MX2019005621A - Metodos y composiciones para el tratamiento del daño del cartilago y la artritis. - Google Patents

Metodos y composiciones para el tratamiento del daño del cartilago y la artritis.

Info

Publication number
MX2019005621A
MX2019005621A MX2019005621A MX2019005621A MX2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A
Authority
MX
Mexico
Prior art keywords
arthritis
compositions
methods
treatment
cartilage damage
Prior art date
Application number
MX2019005621A
Other languages
English (en)
Spanish (es)
Inventor
Johnson Kristen
GOLDHAHN Jörg
Scotti Celeste
Vostiar Igor
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019005621A publication Critical patent/MX2019005621A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019005621A 2016-11-14 2017-11-13 Metodos y composiciones para el tratamiento del daño del cartilago y la artritis. MX2019005621A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421534P 2016-11-14 2016-11-14
US201762560301P 2017-09-19 2017-09-19
PCT/IB2017/057081 WO2018087727A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis

Publications (1)

Publication Number Publication Date
MX2019005621A true MX2019005621A (es) 2019-08-12

Family

ID=60629753

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005621A MX2019005621A (es) 2016-11-14 2017-11-13 Metodos y composiciones para el tratamiento del daño del cartilago y la artritis.
MX2022011897A MX2022011897A (es) 2016-11-14 2019-05-14 Composicion intraarticular para el tratamiento del cartilago y la artritis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011897A MX2022011897A (es) 2016-11-14 2019-05-14 Composicion intraarticular para el tratamiento del cartilago y la artritis.

Country Status (10)

Country Link
US (3) US11351223B2 (https=)
EP (1) EP3538127A1 (https=)
JP (2) JP2019535707A (https=)
KR (2) KR20190084287A (https=)
CN (2) CN109963579A (https=)
AU (2) AU2017357785A1 (https=)
CA (1) CA3043667A1 (https=)
IL (1) IL266361B2 (https=)
MX (2) MX2019005621A (https=)
WO (1) WO2018087727A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024519893A (ja) 2021-05-24 2024-05-21 ノバルティス アーゲー 変形性関節症の治療方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN118251594A (zh) * 2021-11-10 2024-06-25 诺华股份有限公司 用于确定angptl多肽的生物活性的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
MXPA05003978A (es) 2002-10-16 2005-06-22 Scripps Research Inst Sintesis de glicoproteinas.
ES2324608T3 (es) 2002-10-16 2009-08-11 The Scripps Research Institute Incorporacion especifica de sitio de cetoaminoacidos en proteinas.
WO2004094593A2 (en) 2003-04-17 2004-11-04 The Scripps Research Institute Expanding the eukaryotic genetic code
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
CA2580840A1 (en) 2004-09-21 2006-03-30 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
EP1807515A4 (en) 2004-10-27 2008-06-18 Scripps Research Inst Orthogonal translation components for the in vivo incorporation of unnatural amino acids
US7960141B2 (en) 2006-03-09 2011-06-14 The Scripps Research Institute Systems for the expression of orthogonal translation components in eubacterial host cells
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
US8858940B2 (en) * 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) * 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
ES2900815T3 (es) * 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
EP3143026B1 (en) * 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis

Also Published As

Publication number Publication date
AU2020281098B2 (en) 2024-05-02
IL266361B1 (en) 2023-10-01
EP3538127A1 (en) 2019-09-18
JP2023039962A (ja) 2023-03-22
US20250302915A1 (en) 2025-10-02
CN109963579A (zh) 2019-07-02
WO2018087727A1 (en) 2018-05-17
KR20190084287A (ko) 2019-07-16
IL266361A (en) 2019-06-30
MX2022011897A (es) 2022-10-18
US11351223B2 (en) 2022-06-07
US20220331398A1 (en) 2022-10-20
CN117860868A (zh) 2024-04-12
CA3043667A1 (en) 2018-05-17
AU2020281098A1 (en) 2021-01-14
RU2019117884A (ru) 2020-12-14
IL266361B2 (en) 2024-02-01
JP2019535707A (ja) 2019-12-12
RU2019117884A3 (https=) 2021-02-05
KR20240045351A (ko) 2024-04-05
AU2017357785A2 (en) 2019-05-02
AU2017357785A1 (en) 2019-04-11
US20190269754A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
PE20180266A1 (es) Composiciones que comprenden cepas bacterianas
UY37018A (es) Inhibidores bicíclicos de pad4
CR20150466A (es) Péptidos y composiciones para el tratamiento de daño articular
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CO2019014647A2 (es) Composiciones inmunogénicas
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
UY36286A (es) Tratamientos médicos basados en anamorelina